Morning Trend | GeneDx repeatedly tests the bottom area, is the small-cap gene stock at a risk/opportunity tipping point?

GeneDx (WGS.US) has recently maintained a very low and weak oscillation, with the market's risk appetite for the gene technology sector significantly cooling down, and speculative funds continuously exiting. However, after multiple tests of the bottom, it has not been forcefully broken by the main players, and a tense atmosphere is gradually emerging. There are no major news from the company, and the discussion intensity in the market has dropped to freezing point, but some "patient funds" are beginning to logically position themselves at low levels. On the daily chart, the stock price has been repeatedly testing the bottom, and the support below has been tested several times but remains intact; there are few large orders in the market, and the upward momentum is weak, but traces of the main players building positions at low levels occasionally appear. The technical indicators lean towards the bearish side but show signs of holding the bottom line. In the past, small-cap gene stocks often relied on major acquisitions or popular policy themes to make a decisive impact, but now the market is as calm as still water, brewing the next window for significant volatility. For traders who prefer sudden market movements, the risks and opportunities of GeneDx are now approaching a critical point; a breakout on increased volume could attract a rush of outside funds. However, if no new stories emerge for a long time, the sluggishness could easily lead to further declines. Keep a close eye on news developments, unusual large orders, and bottom volume; the next movement could either be a risk release or a rebound from overselling, waiting for the "thunder" to explode opportunities